Basel, Switzerland

Phillipp Krastel

This inventor holds 1 USPTO granted patent. Top assignee: Novartis Ag. Active years: 2012.


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Phillipp Krastel

Introduction: Phillipp Krastel, an accomplished inventor based in Basel, Switzerland, has made significant contributions to the field of medicine through his work on novel antibacterial compounds. With a focus on innovative solutions to combat bacterial infections, Krastel's research has earned him recognition and a patent that enhances the medical industry's arsenal against pathogens.

Latest Patents: Phillipp Krastel holds a patent for "Antibacterial Compounds and Processes for its Production." This invention pertains to a series of novel antibiotic compounds, along with their pharmaceutically acceptable salts and derivatives. The patent also covers methods for producing these compounds, indicating a comprehensive approach to addressing the challenges posed by antibiotic resistance.

Career Highlights: As an inventor working with Novartis AG, one of the leading pharmaceutical companies globally, Krastel has leveraged his skills to push boundaries in antibiotic development. His focus on creating effective treatments places him at the forefront of research aimed at overcoming current and future medical challenges.

Collaborations: Throughout his career, Phillipp Krastel has worked alongside notable colleagues such as Matthew J. Lamarche and Jennifer A. Leeds. These collaborations have likely contributed to the successful development of innovative solutions in pharmaceuticals, reinforcing the importance of teamwork in driving research forward.

Conclusion: Phillipp Krastel's work epitomizes the spirit of innovation and dedication to improving public health. His patent on antibacterial compounds not only showcases his inventive capabilities but also highlights the continuous need for new antibiotics in combating drug-resistant bacteria. As he continues his journey with Novartis AG, his contributions will undoubtedly leave a lasting impact on the field of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…